Mario Siervo , Fionnuala Johnston , Emily Calton , Anthony James , Blossom C.M. Stephan , Amanda K.E. Hornsby , Jeffrey S. Davies , David Burn
{"title":"有认知障碍和无认知障碍帕金森病患者食欲控制的代谢生物标志物","authors":"Mario Siervo , Fionnuala Johnston , Emily Calton , Anthony James , Blossom C.M. Stephan , Amanda K.E. Hornsby , Jeffrey S. Davies , David Burn","doi":"10.1016/j.clnesp.2024.10.167","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Appetite dysregulation in Parkinson's Disease (PD) appears to be linked to physical and cognitive deterioration. PD patients with and without cognitive impairment (CI) were compared to an age-matched control group to explore predictors of appetite control in fasting and post-prandial conditions.</div></div><div><h3>Methods</h3><div>Fifty-five patients were recruited and divided into three groups: twenty controls (age: 74 y, BMI: 25.8 kg/m<sup>2</sup>), nineteen PD patients without CI (72.5 y, 25.1 kg/m<sup>2</sup>) and sixteen PD patients with CI (74.3 y, 24.0 kg/m<sup>2</sup>). Self-reported appetite perception and circulating blood metabolic biomarkers were measured in fasting and over a 3-h post-prandial period. Biomarkers included glucose, insulin, tumour necrosis factor alpha (TNF-α), leptin, acyl-ghrelin, total ghrelin, peptide YY (PYY), glucagon like peptide 1 (GLP-1), insulin growth factor 1 (IGF-1), growth factor (GF) and triglycerides. Patients were then provided with a mixed meal to eat <em>ad libitum</em> with the aim to evaluate links between metabolic biomarkers and control of energy intake.</div></div><div><h3>Results</h3><div>PD patients with CI had a significant lower protein intake (7.4 ± 2.5 g, p = 0.01) compared to controls (21.9 ± 3.1 g) and PD patients without CI (14.3 ± 3.0 g). Post-prandial plasma GLP-1 concentrations were associated with decreased hunger perception (B±SE, −5.3 ± 2.4 mm·h<sup>−1</sup>, p = 0.04). PYY concentrations were significantly associated with GLP-1 in fasting (r = 0.40, p = 0.005) and post-prandial (r = 0.46, p < 0.001) conditions. In a multivariate model, post-prandial PYY concentrations were a significant predictor of <em>ad libitum</em> energy intake in all subjects (B±SE, −87.5 ± 34.9 kcal, p = 0.01) and in patients with PD (B±SE, −106.8 ± 44.9 kcal, p = 0.04).</div></div><div><h3>Conclusions</h3><div>PYY and GLP-1 appeared to influence appetite control in PD patients and their roles merit further investigation.</div></div>","PeriodicalId":10352,"journal":{"name":"Clinical nutrition ESPEN","volume":"64 ","pages":"Pages 425-434"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolic biomarkers of appetite control in Parkinson's disease patients with and without cognitive impairment\",\"authors\":\"Mario Siervo , Fionnuala Johnston , Emily Calton , Anthony James , Blossom C.M. Stephan , Amanda K.E. Hornsby , Jeffrey S. Davies , David Burn\",\"doi\":\"10.1016/j.clnesp.2024.10.167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Appetite dysregulation in Parkinson's Disease (PD) appears to be linked to physical and cognitive deterioration. PD patients with and without cognitive impairment (CI) were compared to an age-matched control group to explore predictors of appetite control in fasting and post-prandial conditions.</div></div><div><h3>Methods</h3><div>Fifty-five patients were recruited and divided into three groups: twenty controls (age: 74 y, BMI: 25.8 kg/m<sup>2</sup>), nineteen PD patients without CI (72.5 y, 25.1 kg/m<sup>2</sup>) and sixteen PD patients with CI (74.3 y, 24.0 kg/m<sup>2</sup>). Self-reported appetite perception and circulating blood metabolic biomarkers were measured in fasting and over a 3-h post-prandial period. Biomarkers included glucose, insulin, tumour necrosis factor alpha (TNF-α), leptin, acyl-ghrelin, total ghrelin, peptide YY (PYY), glucagon like peptide 1 (GLP-1), insulin growth factor 1 (IGF-1), growth factor (GF) and triglycerides. Patients were then provided with a mixed meal to eat <em>ad libitum</em> with the aim to evaluate links between metabolic biomarkers and control of energy intake.</div></div><div><h3>Results</h3><div>PD patients with CI had a significant lower protein intake (7.4 ± 2.5 g, p = 0.01) compared to controls (21.9 ± 3.1 g) and PD patients without CI (14.3 ± 3.0 g). Post-prandial plasma GLP-1 concentrations were associated with decreased hunger perception (B±SE, −5.3 ± 2.4 mm·h<sup>−1</sup>, p = 0.04). PYY concentrations were significantly associated with GLP-1 in fasting (r = 0.40, p = 0.005) and post-prandial (r = 0.46, p < 0.001) conditions. In a multivariate model, post-prandial PYY concentrations were a significant predictor of <em>ad libitum</em> energy intake in all subjects (B±SE, −87.5 ± 34.9 kcal, p = 0.01) and in patients with PD (B±SE, −106.8 ± 44.9 kcal, p = 0.04).</div></div><div><h3>Conclusions</h3><div>PYY and GLP-1 appeared to influence appetite control in PD patients and their roles merit further investigation.</div></div>\",\"PeriodicalId\":10352,\"journal\":{\"name\":\"Clinical nutrition ESPEN\",\"volume\":\"64 \",\"pages\":\"Pages 425-434\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical nutrition ESPEN\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405457724015055\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nutrition ESPEN","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405457724015055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Metabolic biomarkers of appetite control in Parkinson's disease patients with and without cognitive impairment
Background
Appetite dysregulation in Parkinson's Disease (PD) appears to be linked to physical and cognitive deterioration. PD patients with and without cognitive impairment (CI) were compared to an age-matched control group to explore predictors of appetite control in fasting and post-prandial conditions.
Methods
Fifty-five patients were recruited and divided into three groups: twenty controls (age: 74 y, BMI: 25.8 kg/m2), nineteen PD patients without CI (72.5 y, 25.1 kg/m2) and sixteen PD patients with CI (74.3 y, 24.0 kg/m2). Self-reported appetite perception and circulating blood metabolic biomarkers were measured in fasting and over a 3-h post-prandial period. Biomarkers included glucose, insulin, tumour necrosis factor alpha (TNF-α), leptin, acyl-ghrelin, total ghrelin, peptide YY (PYY), glucagon like peptide 1 (GLP-1), insulin growth factor 1 (IGF-1), growth factor (GF) and triglycerides. Patients were then provided with a mixed meal to eat ad libitum with the aim to evaluate links between metabolic biomarkers and control of energy intake.
Results
PD patients with CI had a significant lower protein intake (7.4 ± 2.5 g, p = 0.01) compared to controls (21.9 ± 3.1 g) and PD patients without CI (14.3 ± 3.0 g). Post-prandial plasma GLP-1 concentrations were associated with decreased hunger perception (B±SE, −5.3 ± 2.4 mm·h−1, p = 0.04). PYY concentrations were significantly associated with GLP-1 in fasting (r = 0.40, p = 0.005) and post-prandial (r = 0.46, p < 0.001) conditions. In a multivariate model, post-prandial PYY concentrations were a significant predictor of ad libitum energy intake in all subjects (B±SE, −87.5 ± 34.9 kcal, p = 0.01) and in patients with PD (B±SE, −106.8 ± 44.9 kcal, p = 0.04).
Conclusions
PYY and GLP-1 appeared to influence appetite control in PD patients and their roles merit further investigation.
期刊介绍：
Clinical Nutrition ESPEN is an electronic-only journal and is an official publication of the European Society for Clinical Nutrition and Metabolism (ESPEN). Nutrition and nutritional care have gained wide clinical and scientific interest during the past decades. The increasing knowledge of metabolic disturbances and nutritional assessment in chronic and acute diseases has stimulated rapid advances in design, development and clinical application of nutritional support. The aims of ESPEN are to encourage the rapid diffusion of knowledge and its application in the field of clinical nutrition and metabolism. Published bimonthly, Clinical Nutrition ESPEN focuses on publishing articles on the relationship between nutrition and disease in the setting of basic science and clinical practice. Clinical Nutrition ESPEN is available to all members of ESPEN and to all subscribers of Clinical Nutrition.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
